Evolocumab Tied to 20% Lower Risk of Myocardial Infarction vs Ezetimibe in Real-World Study
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The report was published on 06 de novembro de 2026 às 04:20 by Patient Care Online and is part of the World news coverage.
Quick answers
Who reported this story?
It was first reported by Patient Care Online on 06 de novembro de 2026 às 04:20.
What is the category?
It is filed under World news on Rio Warzone News.
